Zoetis Pharmaceuticals (002317.SZ): Ethical approval obtained for two Phase III clinical trials of the innovative drug RAY1225 injection for lowering blood sugar levels.

News from Securities Times APP, Zhongsheng Pharmaceuticals (002317.SZ) announced that the innovative polypeptide drug RAY1225 injection developed by its controlling subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang") has obtained ethical review approval from the leading unit Beijing University People's Hospital for two Phase III clinical trials (SHINING-2 and SHINING-3) for patients with type 2 diabetes (T2DM).